PD
PACB icon

Point72 (DIFC)’s Pacific Biosciences PACB Stock Holding History

Point72 (DIFC)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.47M Buy
4,270,137
+1,811,137
+74% +$2.45M 0.36% 71
2025
Q2 		$3.05M Buy
+2,459,000
New +$2.84M 0.12% 224

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

Point72 (DIFC)'s PACB Position: Q3 2025 in Review

Point72 (DIFC) increased its Pacific Biosciences (PACB) stake by 74% in Q3 2025, buying an estimated $2.45M and bringing the position to 4,270,137 shares worth $5.47M. The position accounts for 0.36% of the portfolio, ranked #71.

Point72 (DIFC) first reported a position in PACB in Q2 2025 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • Point72 (DIFC) held 4,270,137 shares of Pacific Biosciences worth $5.47M as of Q3 2025.
  • Point72 (DIFC) bought 1,811,137 Pacific Biosciences shares in Q3 2025, an estimated $2.45M.
  • Pacific Biosciences made up 0.36% of Point72 (DIFC)'s portfolio in Q3 2025, its #71 holding.
  • Point72 (DIFC) first reported a position in Pacific Biosciences in Q2 2025 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.